AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The NIAGARA-2 study, officially titled ‘A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer,’ aims to investigate the effectiveness of perioperative durvalumab combined with cisplatin-based neoadjuvant chemotherapy. This study seeks to expand on previous data to improve treatment outcomes for patients with muscle-invasive bladder cancer.
The intervention involves the use of durvalumab, an anti-PD-L1 antibody, in combination with chemotherapy agents. Two cohorts are being tested: one with ddMVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) and another with gemcitabine and cisplatin, both aiming to enhance the immune response against cancer cells.
This interventional study follows a single-group assignment model without masking, focusing primarily on treatment. It is designed to evaluate the safety and efficacy of the drug combinations in a real-world clinical setting.
The study began on May 15, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 24, 2025, indicating ongoing recruitment and progress.
For investors, the advancement of the NIAGARA-2 study could bolster AstraZeneca’s position in the oncology market, potentially influencing stock performance positively. As the study progresses, it may also impact investor sentiment, especially if interim results show promising efficacy compared to competitors.
The NIAGARA-2 study is currently recruiting, with further details available on the ClinicalTrials portal.